Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Appian Corp (APPN) vs McKesson Corporation (MCK) Price & Performance

Appian Corp
McKesson Corporation

Price performance

Price movement over the last 24 hours

Key statistics

Appian Corp vs McKesson Corporation — how do they compare? Appian Corp trades at $25.5 (market cap $1.86B), while McKesson Corporation trades at $809.88 (market cap $94.36B). The key difference: McKesson Corporation is far larger — about 50.7× Appian Corp's market cap, and McKesson Corporation pays a 0.41% dividend while Appian Corp pays none. Which is the better fit depends on your goals.

APPNMCK
Market Cap
$1.86B$94.36B
Sector
TechnologyHealth
52-Week High
$45.64$995.69
52-Week Low
$18.72$659.01
Enterprise Value
$1.95B$99.00B
Dividend Yield
0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Appian Corp

Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.

The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.

McKesson Corporation

McKesson (MCK) trades at $805.96, up 1.66% with strong bullish momentum near its pivot point of $799. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations, and revenue growth accelerating to $359.05B in 2025. Analyst sentiment is overwhelmingly positive with an 80% buy rating and a $932.83 consensus price target, while recent corporate developments include a strategic investment in Medical-Surgical Solutions with Apollo Funds.

The outlook remains favorable given robust cash flow generation and expanding profitability, though risks include policy uncertainties and high leverage. Upside potential is supported by valuation discounts relative to sector peers and continued execution in specialty pharma and oncology services.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK